Veracyte Says Phase III STAMPEDE Analysis Shows Decipher Prostate Test Predicts Benefit Of Adding Abiraterone To ADT In Very High-Risk Nonmetastatic Prostate Cancer, With 10-11% Absolute Benefit At Five Years For High-Scoring Patients Versus 2% For Lower Scores
Share
Why It Matters
Veracyte's prostate cancer test showed it can predict which patients benefit most from extra medicine. This suggests the test helps doctors choose the right treatment for each patient.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.